Genomic Cancer Panel and Profiling Markets 2027–2031

Genomic Cancer Panel and Profiling Markets: Market Forecast, Competitive Landscape, Technology and Partnering Opportunities, 2027–2031 (October 2026)

Global forecasts by cancer type, clinical use, panel size, sample and customer, for 14 countries and regions, with 97 company profiles.

See the Table of Contents. GET the Free Sample of this Report.

Many organizations subscribe to all or some of our reports. You may already have free access to this report. FIND out Here.

Our Take

Cancer gene panels are getting bigger and moving into blood. The market grows from $6.54 billion in 2026 to $11.5 billion in 2031, at 11.9% a year. Comprehensive genomic profiling takes most of the new spending, blood-based panels catch up with tissue, and MRD monitoring and screening are the fastest-growing uses, while small hotspot panels stall.

Market Size 2026: USD $6.54B Market Size 2031: USD $11.5B CAGR: 11.9%

Situation Analysis: what is really happening

• Comprehensive profiling takes over. Comprehensive genomic profiling grows 17.2% a year from $2,518 million to $5,578 million, rising from 38.5% to 48.5% of the market and taking 62% of new spending. Hotspot panels grow only 2.6% a year.
• Blood catches up with tissue. Blood-based panels grow 19.6% a year from $1,995 million to $4,888 million and take 58% of new spending; their share rises from 30.5% to 42.5%. The FDA approved a next-generation Guardant360 Liquid CDx in May 2026.
• Monitoring and screening grow fastest. MRD & Monitoring grows 21.1% a year to $2,128 million and Screening & Early Detection 23.4% a year to $748 million. Therapy Selection & CDx remains the largest use at $2,387 million in 2026.
• Kits challenge central laboratories. Medicare set a national payment of $2,989.55 for Illumina's TruSight Oncology Comprehensive kit, and Illumina and Labcorp expanded their collaboration on distributed CGP. Clinical Laboratories still reach 77.5% of the market in 2031.
• Germline panels for more patients. NCCN now recommends multigene germline panel testing for all colorectal, endometrial and gastric cancer patients. Hereditary Risk & Germline is worth $1,472 million in 2026.
• Lung leads; prostate and China grow fastest. Lung is the largest cancer type at $1,602 million and prostate grows fastest at 15.0% a year. China grows 14.4% a year from $573 million to $1,122 million, while the USA reaches 43.3% of the market.

Company Analysis: who is positioned, who is exposed

• Foundation Medicine (Roche): The largest set of companion diagnostic claims, with 100 indications across its tests by 2025.
• Illumina: TruSight Oncology Comprehensive, a 500+ gene kit with CDx claims, gained a national Medicare rate from January 2026, and Roche's new Axelios sequencer adds competition in sequencing.
• Caris Life Sciences: About 48,300 MI Profile cases in the second quarter of 2026, with revenue up 45% and 2026 guidance raised to $1.03–1.04 billion.
• Tempus AI: Owns Ambry Genetics, which passed one million combined RNA and DNA hereditary tests, and agreed to acquire Personalis and its whole-exome platform.
• Guardant Health and Natera: A next-generation Guardant360 Liquid CDx, and Signatera CDx as the first MRD companion diagnostic.
• Thermo Fisher Scientific, Labcorp and NeoGenomics: The 24-hour Oncomine Dx Express Test, PGDx elio tissue complete (505 genes) and PanTracer Pro (500+ genes) compete for hospital and community testing.

Plus 86 more company profiles, each one to two pages with a fact box covering website, headquarters, ownership, revenue, employees and key products.

Questions this report answers

• How fast will comprehensive genomic profiling replace smaller targeted and hotspot panels?
• How large can blood-based panels and MRD monitoring become, and how quickly will they catch up with tissue?
• Will distributable CGP kits take testing away from central laboratories?
• Which cancers, clinical uses and customers will add the most new spending?
• Who are the leading companies and partners, and what are panel companies selling for?
• How large is each country market, and how fast is China growing?

What's inside

• 441 pages, 24 chapters, 70 tables and 53 figures
• Forecasts for 2027–2031 from a 2026 base year, by cancer type, clinical use, panel size, sample and customer, for 14 countries and regions
• Approved test landscape, clinical evidence and test pipeline, technology and sequencers, pharma partnerships and business models
• Regulation and reimbursement, intellectual property, litigation and pricing, a China chapter, a deal database and laboratory operations
• 10 market-moving developments from 2025 and 2026, SWOT, Porter's Five Forces and strategic recommendations
• 97 company profiles
• Download the Table of Contents (PDF)

Who buys this report

• Diagnostics executives and business development teams: size panel and profiling opportunities by panel size, sample and clinical use, and find partners and acquisition targets.
• Laboratory directors: decide whether to send out or bring in comprehensive profiling, and plan for blood-based and MRD testing.
• Investors and analysts: model the growth of CGP, liquid biopsy and MRD and benchmark deal values.
• Sequencer, reagent and software suppliers: judge demand in clinical, pharma and research laboratories.

Use independent research that makes you the expert. Your credit card order sends the report to your inbox instantly. Check all your licensing options, but don't worry: your order is available as a credit if you wish to upgrade.

See the Table of Contents. GET the Free Sample of this Report.

ABOUT THE LEAD AUTHOR

Mr. Greg Powell, B.Sc., M.B.A., is the President of Howe Sound Research. His education includes:

Finance for Senior Executives - Harvard Business School

Market Research - Burke Institute

M.B.A. (Finance and Policy) - University of British Columbia

B.Sc. (Chemistry) - University of British Columbia

He is an experienced business and clinical professional. He is co-author of the paper "The Radioimmunoassay of Angiotensinogen by Antibody Trapping." He has worked in laboratory testing and management for over 20 years.